Hook / Thesis
Evolv Technologies is one of the clearest commercialization stories in AI-powered physical security: the company sells sensor- and AI-based weapons-detection systems to casinos, schools, healthcare facilities and venues. The business is scaling fast enough to justify attention - management has raised full-year revenue guidance to $175-$180 million - yet shares trade well below prior peaks because of an ongoing internal-control investigation and periodic volatility. That creates a potential re-entry point for disciplined longs who size positions around governance risk.
I'm recommending a long entry at $5.90 with a target of $8.50 and a stop at $4.86long term (180 trading days) to give the company time to convert pipeline into revenue, realize margin improvement, and resolve or substantially reduce the reporting overhang.
Why the market should care
Evolv makes and sells AI-based security screening hardware and software that replaces slower, labor-intensive metal detection and manual screening. The product sells into large addressable markets - education, healthcare, entertainment, and industrial - where customers trade a degree of capital expense for faster throughput, fewer false positives, and lower labor costs. The market narrative is straightforward: customers modernize screening to improve safety and throughput, and Evolv sells a platform with recurring software and service revenue potential.
Business snapshot and recent performance
The company currently trades at about $5.90 per share with a market capitalization near $1.04 billion. Management raised full-year sales guidance to $175-$180 million on 05/13/2026 after quarterly results that beat sales estimates by $2.6 million; that same release coincided with a sharp stock reaction but not with a deterioration in the core business. Historical datapoints worth noting:
- Q2 2025 revenue was reported at $32.5 million with 29% year-over-year growth and positive adjusted EBITDA of $2.0 million (reported 08/15/2025).
- Management commentary and updated guidance (05/13/2026) point to a much higher revenue run-rate than the prior guidance, implying sustained demand.
- The company has demonstrated strong top-line growth historically - an earlier note observed roughly 57% year-over-year revenue growth when reference was made to the company's trajectory.
Balance sheet and valuation framing
On valuation, Evolv is not cheap in absolute multiples: price-to-sales near 6.3x and price-to-book above 8x reflect a growth premium priced into a still-unprofitable company (last reported GAAP EPS around -$0.20). Enterprise value is roughly $982 million, and free cash flow was negative approximately -$4.35 million in the most recent snapshot. That said, the company is showing the early signs of scale - positive adjusted EBITDA in Q2 2025 and materially raised FY 2026 revenue guidance - which supports a higher multiple if growth persists and unit economics improve.
Put another way: the market is valuing the company as a high-growth, early-stage software/hardware hybrid with meaningful operating leverage potential, but the valuation also embeds risk related to execution and governance. The current price gives investors exposure to upside if management converts guidance into delivered results, while leaving room for downside if the investigation or execution stalls growth.
| Metric | Value |
|---|---|
| Current price | $5.90 |
| Market cap | ~$1.04B |
| Enterprise value | ~$981.7M |
| Price / Sales | 6.3x |
| GAAP EPS (latest) | -$0.20 |
| FY 2026 revenue guidance | $175 - $180M |
| 52-week range | $4.865 - $8.91 |
Technical and sentiment context
The technical picture is neutral-to-mildly constructive: the 10-day SMA (~$5.58) sits below price, the 20-day (~$5.86) is close to current levels, and the 50-day (~$6.28) is above, implying resistance into the mid-$6s. RSI around 47.7 is neutral. Short interest is meaningful but not extreme: roughly 8 million shares short (settlement 06/15/2026) and recent short-volume data show active short trading. Average daily volume is about 2.7 million, so the stock is liquid enough for position management.
Trade plan (actionable)
Entry: $5.90
Stop Loss: $4.86 (just above the 52-week low of $4.865 to respect structural support)
Target: $8.50 (approaching the prior 52-week high of $8.91, allows for profit taking while leaving some upside if momentum continues)
Time horizon: long term (180 trading days) - allow time for revenue realization against the raised FY 2026 guidance and for any meaningful developments on the internal-control overhang.
Rationale: the stop limits downside to a clear structural support near the 52-week low, while the target captures a re-rating back toward prior highs if growth and margin trends normalize. The 180-trading-day horizon aligns with typical timelines for resolution of investigations and for multiple quarters of operational execution to be reported.
Catalysts
- Delivery beats and sustained revenue growth - continued execution and visibility on order flow following the raised guidance (catalyst: quarterly reports over the next two quarters that meet or beat guidance).
- Margin expansion - progression from adjusted EBITDA positivity toward consistent operating leverage that drives free-cash-flow inflection.
- Resolution or material progress in the internal-control investigation - any clearance or remediation plan would remove a headline overhang and could unlock valuation upside.
- Large contract announcements or notable deployments in gaming, education, or healthcare - visible enterprise wins would accelerate adoption and cadence of revenue.
Risks (at least four) and a counterargument
- Governance / reporting risk: The company is under investigation for potential financial reporting issues (public report 10/20/2025). If the inquiry finds material misstatements, the stock could suffer a material downward repricing and legal costs could increase.
- Execution risk: Scaling a hardware-plus-software business requires supply chain discipline, installation capabilities, and effective service economics. Any slippage in deployments or cost overruns would pressure margins and cash flow.
- Profitability & cash flow: The company remains unprofitable on GAAP (-$0.20 EPS) and free cash flow was negative (~-$4.35M). Continued cash burn would necessitate funding or dilution if cash generation doesn’t improve.
- Valuation compression risk: The current multiples (P/S ~6.3x) already price in a fair amount of growth. If growth decelerates or multiple contraction occurs, downside could be steep relative to the entry.
- Sentiment & short pressure: Meaningful short interest and episodes of aggressive short-volume trading have created volatility; the stock can gap lower on negative headlines and take time to recover.
Counterargument: One credible counterargument is that the internal-control investigation signals deeper issues in revenue recognition or accounting that would impair the company's ability to sustain growth. If confirmed, the business could face restatements, weakened customer confidence, and a protracted valuation reset. That outcome would argue against a long position until the company has resolved the matter and demonstrated clean, repeatable financials.
What would change my mind
I will reconsider the long thesis if any of the following occur:
- Material adverse findings in the investigation or financial restatements.
- Consecutive quarters of revenue misses or a material downward revision to FY guidance.
- Clear deterioration of liquidity that forces dilutive financing without a path to sustained cash-flow breakeven.
Conversely, I would add to the position if management delivers several quarters of revenue beats, demonstrates meaningful margin improvement, and provides a credible remediation plan or positive update on the internal-control matter.
Bottom line
Evolv is a focused play on AI-driven physical security with convincing early traction and a recently upgraded revenue outlook. The governance overhang and the still-negative GAAP profitability justify caution and position sizing discipline, but the current price around $5.90 offers a reasonable risk-reward for a long-term trade that assumes execution and governance remediation. Enter at $5.90, stop at $4.86, target $8.50, and give the company up to 180 trading days to validate the thesis.
Trade idea snapshot: Long EVLV; Entry $5.90; Stop $4.86; Target $8.50; Time horizon: long term (180 trading days); Risk level: medium.